ESBRIET 267 mg, film-coated tablets
Active ingredients: PIRFÉNIDONE
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tabletConditionnement multiple de 252 (3 boîtes contenant chacune (4 x 21) plaquette(s) thermoformée(s) PVC (ACLAR RX) polytrifluorochloroéthylène) comprimésorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ESBRIET 267 mg, comprimés pelliculés
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- Conditionnement multiple de 252 (3 boîtes contenant chacune (4 x 21) plaquette(s) thermoformée(s) PVC (ACLAR RX) polytrifluorochloroéthylène) comprimés
- Marketing authorisation holder
- HAC PHARMA
- Reimbursement according to BDPM
- 30%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- fibrose pulmonaire idiopathique légère à modérée, dans certains cas et selon certaines conditions précisément définis uniquement. ; JOURNAL OFFICIEL ; 15/10/15
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Mar 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66527665CIP73010922CIP133400930109229Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PIRFÉNIDONEcomprimé | 267 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: PIRFENIDONE 267 mg - ESBRIET 267 mg, comprimé pelliculé